Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (230)	6/21/2004 4:36:35 AM
From: tuck	Respond to of 510

[A Technical Triade for Proteomic Identification and Characterization of Cancer Biomarkers.] >>Cancer Res. 2004 Jun 15;64(12):4099-4104. A Technical Triade for Proteomic Identification and Characterization of Cancer Biomarkers. Melle C, Ernst G, Schimmel B, Bleul A, Koscielny S, Wiesner A, Bogumil R, Moller U, Osterloh D, Halbhuber KJ, Von Eggeling F. Core Unit Chip Application, Institute of Human Genetics and Anthropology, Clinic of ENT Diseases, and Institute of Anatomy II, Friedrich-Schiller-University, Jena. Biomarkers are needed to elucidate the biological background and to improve the detection of cancer. Therefore, we have analyzed laser-microdissected cryostat sections from head and neck tumors and adjacent mucosa on ProteinChip arrays. Two differentially expressed proteins (P = 3.34 x 10(-5) and 4.6 x 10(-5)) were isolated by two-dimensional gel electrophoresis and identified as S100A8 (calgranulin A) and S100A9 (calgranulin B) by in-gel proteolytic digestion, peptide mapping, tandem mass spectrometry analysis, and immunodepletion assay. The relevance of these single marker proteins was evaluated by immunohistochemistry. Positive tissue areas were reanalyzed on ProteinChip arrays to confirm the identity of these proteins. As a control, a peak with low P was identified as calgizzarin (S100A11) and characterized in the same way. This technical triade of tissue microdissection, ProteinChip technology, and immunohistochemistry opens up the possibility to find, identify, and characterize tumor relevant biomarkers, which will allow the movement toward the clonal heterogeneity of malignant tumors. Taking this approach, proteins were identified that might be responsible for invasion and metastasis.<< The bonus here is that the proteins causing peaks that have the most clinical relevance are identified. Pretty labor intensive, but once identified, finding 'em again is relatively easy. Cheers, Tuck

To: tuck who wrote (230)	6/21/2004 4:38:26 AM
From: tuck	Read Replies (1) \| Respond to of 510

[Proteomic fingerprinting of human immunodeficiency virus type 1associated dementia from patient monocyte-derived macrophages] >>J Neurovirol. 2004;10(Supplement 1):74-81. Proteomic fingerprinting of human immunodeficiency virus type 1associated dementia from patient monocyte-derived macrophages: A case study. Wojna V, Carlson K, Luo X, Mayo R, Melez L, Kraiselburd E, Gendelman H. 1 The Departments of Microbiology and Specialized NeuroSciences Program University of Puerto Rico Medical Sciences Campus San Juan Puerto Rico. The emergence of a subset of circulating monocytes during human immunodeficiency virus type 1 (HIV-1) disease has been shown to correlate with cognitive impairment. Thus, it is hypothesized that diagnostic protein profiles may be obtained from these cells from patients with or at risk for HIV-1associated dementia (HAD). To address this possibility, we used ProteinChip assays to define a unique monocyte-derived macrophage (MDM) protein fingerprint during HAD and whether it is affected by highly active antiretroviral therapy (HAART). The study included five Hispanic women, one with HAD, two HIV-1infected without cognitive impairment, and two seronegative controls. All patients were matched by age and immune status. Monocytes were recovered from the peripheral blood leukocytes by Percoll gradient centrifugation and allowed to differentiate in vitro for 7 days. Cell lysates and supernatants were collected from the MDM and analyzed by surface enhanced laser desorption/ionizationtime of flight ProteinChip assays. Seven unique protein peaks between 3.0 and 20.0 kDa were found in the HAD MDM sample. Each of these proteins were abrogated after HAART. Additional studies extending this one time point determination would serve to confirm the general utility of MDM protein profiling for the diagnosis and monitoring of HAD.<< Cheers, Tuck